PEN
HEALTHCAREPenumbra Inc
$324.19+0.33 (+0.10%)PRE
Live · NYSE · May 9, Close
AI Insight
What's Moving PEN Today?
No stock-specific AI insight has been generated for PEN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$221.26$362.41
$324.19
Fundamentals
Market Cap$12.8B
P/E Ratio74.7
EPS$4.34
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume341K
Avg Volume (10D)—
Shares Outstanding39.3M
PEN News
20 articles- Assessing Penumbra (PEN) Valuation As Growth Expectations Meet A Premium P/E MultipleYahoo Finance·May 7, 2026
- Penumbra (PEN) Misses Q1 Earnings EstimatesYahoo Finance·May 6, 2026
- Penumbra, Inc. Reports First Quarter 2026 Financial ResultsYahoo Finance·May 6, 2026
- ALC vs. PEN: Which Stock Should Value Investors Buy Now?Yahoo Finance·May 5, 2026
- NovoCure Stock Shows Strength With RS Upgrade; Investors Should Watch For Next EntryYahoo Finance·May 4, 2026
- Boston Scientific AGM: $20B 2025 Sales, Governance Votes Pass, Special Meeting Proposals FailMarketbeat·May 2, 2026
- Massively Disappointing Boston Scientific (BSX) Stock Could Be Due for a ComebackBarchart·Apr 28, 2026
- 3 Reasons Why Penumbra (PEN) Is a Great Growth StockYahoo Finance·Apr 27, 2026
- Boston Scientific Q1 Earnings Call HighlightsMarketbeat·Apr 24, 2026
- EY on the current state of the medtech industryMedicaldevice-network·Apr 20, 2026
- Boston Scientific Corporation (BSX) Price Target Lowered at Mizuho Ahead of Q1 Medical Device EarningsYahoo Finance·Apr 17, 2026
- Peninsula Energy Limited (ASX:PEN): When Will It Breakeven?Yahoo Finance·Apr 17, 2026
- A Look At Boston Scientific (BSX) Valuation After The Penumbra Acquisition And Recent Shareholder ReturnsYahoo Finance·Apr 15, 2026
- Citi Reiterates Buy rating for Boston Scientific (BSX)Yahoo Finance·Apr 14, 2026
- New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism PatientsYahoo Finance·Apr 13, 2026
- 1 Mid-Cap Stock on Our Buy List and 2 We IgnoreYahoo Finance·Apr 13, 2026
- 3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)Yahoo Finance·Apr 10, 2026
- Penumbra Sale To Boston Scientific Sparks Review Of Deal ValueYahoo Finance·Apr 10, 2026
- E2 raises $80M to market thrombectomy platformMedtechdive·Apr 9, 2026
- Penumbra (NYSE:PEN): Strongest Q4 Results from the Medical Devices & Supplies - Cardiology, Neurology, Vascular GroupYahoo Finance·Apr 7, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$323.86
Day High$0.00
Day Low$0.00
52 Week High$362.41
52 Week Low$221.26
52-Week Range
$221.26$362.41
$324.19
Fundamentals
Market Cap$12.8B
P/E Ratio74.7
EPS$4.34
Dividend Yield—
Dividend / Share—
ROE0.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume341K
Avg Volume (10D)—
Shares Outstanding39.3M
About Penumbra Inc
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company is headquartered in Alameda, California.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—